Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Atea Pharmaceuticals (AVIR) Assets Average (2020 - 2026)

Atea Pharmaceuticals' Assets Average history spans 7 years, with the latest figure at $291.1 million for Q1 2026.

  • Quarterly Assets Average fell 35.63% to $291.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $291.1 million through Mar 2026, down 35.63% year-over-year, with the annual reading at $389.9 million for FY2025, 26.4% down from the prior year.
  • Assets Average came in at $291.1 million for Q1 2026, down from $329.1 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $745.0 million in Q1 2022 to a low of $291.1 million in Q1 2026.
  • The 5-year median for Assets Average is $574.0 million (2024), against an average of $544.8 million.
  • Year-over-year, Assets Average dropped 10.44% in 2023 and then crashed 35.63% in 2026.
  • Atea Pharmaceuticals' Assets Average stood at $676.6 million in 2022, then dropped by 11.1% to $601.5 million in 2023, then fell by 20.57% to $477.8 million in 2024, then crashed by 31.13% to $329.1 million in 2025, then decreased by 11.53% to $291.1 million in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Assets Average are $291.1 million (Q1 2026), $329.1 million (Q4 2025), and $367.3 million (Q3 2025).